A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of beta-amyloid load in an AD cohort

作者：Pedrini, Steve; Gupta, Veer B.; Hone, Eugene; Doecke, James; O'Bryant, Sid; James, Ian; Bush, Ashley I.; Rowe, Christopher C.; Villemagne, Victor L.; Ames, David; Masters, Colin L.; Martins, Ralph N.^*

来源：Scientific Reports, 2017, 7(1): 14057.

DOI：10.1038/s41598-017-14020-9

• PRECLINICAL ALZHEIMERS-DISEASE
• REMITTING MULTIPLE-SCLEROSIS
• MILD COGNITIVE IMPAIRMENT
• AUTOIMMUNE INFLAMMATION
• FRONTOTEMPORAL DEMENTIA
• CEREBROSPINAL-FLUID
• APOLIPOPROTEIN-E
• CONTROLLED-TRIAL
• NEUROPEPTIDE-Y
• INTERLEUKIN-12

Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE epsilon 4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE e4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.

• 出版日期2017-10-25
• 单位CSIRO